Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
|
DR LALCHANDANI LABS LIMITED Our Company was originally Incorporated as partership firm at New Delhi vide Partnership Agreement dated 15th Day of September, 2011 in the name of Dr. A Lalchandani Pathology Laboratories. Thereafter the Partnership Firm was taken over by M/s Dr Lalchandani Labs Limited incorporated under the provisions of Companies Act, 2013 vide certifcate of Incorporation dated 2nd August. 2017 issued by the Registrar of Companies. Delhi vide agreement dated 31 st August, 2017. The Corporate Identification Number of our Company is U85320DL2017PLC321605. For further details of incorporation, change of name and registered office of our Company, please refer to chapter titled 'General Information' and 'Our History and Corporate Structure' beginning on page 47 and page 137 respectively of the Prospectus. Registered Office: M-20 Basement, Greater Kailash-1,
New Delhi 110048, Delhi, India PROMOTERS OF OUR COMPANY: MR. ARJAN LAL CHANDANI. MR. MOHIT LAL CHANDANI AND MRS. ANCHAL GUPTA BASIS OF ALLOTMENT PUBLIC ISSUE OF 14,00,000 EQUITY SHARES OF RS 10 EACH ('EQUITY SHARES') OF DR LALCHANDANI LABS LIMITED ('DLCL' OR THE 'COMPANY' OR THE 'ISSUER') FOR CASH AT A PRICE OF RS.30 PER SHARE INCLUDING A SHARE PREMIUM OF RS. 20 PER SHARE (THE 'ISSUE PRICE'), AGGREGATING TO RS. 420.00 LACS ('THE ISSUE'), OF WHICH. 72,000 EQUITY SHARES OF RS.10 EACH FOR CASH AT A PRICE OF RS.30 PER SHARE INCLUDING A SHARE PREMIUM OF RS. 20 PER SHARE AGGREGATING TO RS. 21 60 LACS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKERS TO THE ISSUE (THE 'MARKET MAKER RESERVATION PORTION'). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 13,28,000 EQUITY SHARES OF RS.10 EACH AT A PRICE RS.30 PER SHARE INCLUDING A SHARE PREMIUM OF RS. 20 PER SHARE AGGREGATING TO RS. 398.40 LACS IS HEREINAFTER REFERRED TO AS THE 'NET ISSUE'. THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 32.31% AND 30.65% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF THE COMPANY In terms of Prospectus dated 11th April, 2018 and as per Regulation 43 (4) of SEBI (ICDR) Regulations, 2009 wherein a minimum of 50 % of the Net Issue to Public shall be made available to shall be made available to shall be intially made available to retail Individual Investors as the case may be. The balance net offer of shares to the public shall be made available for allotment to a) individual applicants other than retail investors and b) other investors including corporate bodies / Institutions irrespective of no. of shares applied for. The unsubscribed portion of the net offer to any one of the categories specified in (a) or (b) shall/may be made available for allocation in any other category, if so required Explanation: For the purpose of Regulation 43 (4) of SEBI (ICDR) Regulations. 2009, if the retail individual investor is entitled to more than fifty percent, on proportionate basis, the retail individual investors shall be allocated that higher percentage. THE FACE VALUE OF THE EQUITY SHARES IS RS. 10/- EACH AND The Equity Shares offered through the Prospectus are proposed to be listed on the SME plattorm of BSE Limited ('BSE') in terms of the chapter XB of the SEBI (ICDR) Regulations, 2009 as amended from time to time, Company has received an approval letter dated 11th April, 2018, from BSE for using its name in the offer document for listing of our Shares on the SME platform of BSE. The designated stock exchange is BSE Limited. All Applicants are mandatorily to participate in the issue through APPLICATION SUPPORTED BY BLOCKED AMOUNT ('ASBA') process by providing the details of the respective bank accounts in which the corresponding application amounts were blocked by Sell Certified Syndicate Banks (The 'SCSBs') SUBSCRIPTION DETAILS The Issue has received 1060 applications for 62,24,000 Equity Shares (Including Market Maker Application of 72,000 Equity Shares) resulting 4.446 times suoscnption 129 applications of aggregating 16,20,000 Equity Shares were not banked hence 931 applications for 46,04,000 Equity Shares (Including Market Maker Application of 72,000 Equity Shares) resulting 3.289 times subscription was considered The details of the applications received in the Issue (before technical rejections) are as follows: Detail of the Applications Received (Before Technical Rejection & withdrawal of application):
The details of applications rejected by the Registrar on technical grounds (including withdrawals) are detailed below.
Details of the Valid Applications Received (After Technical Rejection & withdrawal):
ALLOCATION: The Basis of Allotment was finalised in consultation with the Designated Stock Exchange - BSE Limited on 4th May, 2018 A. Allocation to Market Maker (After Technical Rejections & Withdrawal): The Basis of Allotment to the Market Maker, at the issue price of Rs. 30/- per Equity Share, was finalised in consultation with BSE. The category was subscribed by 1.000 bme The total number of shares allotted in this category is 72,000 Equity shares in full out of reserved portion of 72.000 Equity Shares B Allocation to Retail Individual Investors (After Technical Rejections & Withdrawal): The Basis of Allotment to the Retail Individual Investors, at the Issue price of Rs 30/- per Equity Share was finalized m consultation with BSE The category was subscribed by 5.211 times Total number of shares allotted in this category is 10,40,000 Equity Shares. The category wise basis of allotment is as under;
C. Allocation to Non Retail Investors (After Technical Rejections & Withdrawal): The Basis of Allotment to the Non Ratal Investors, at the Issue price of Rs30/- per Equity Share, was finalized in consultation with BSE. The category was subsenbed by 1.446 times Total number of shares allotted In this category is 2,88,000 Equity Shares. The category wise basis of allotment is as under
The Board of Directors of the Company at its meeting held on 5th May, 2018 has taken on record the Basis of Allocation of Equity Shares approved by the Designated Stock Exchange viz. BSE and has authorized the corporate action for the transfer of the Equity Shares / dispatch of share certificates to various successful applicants. The allotment advice and/or rejection letters are being dispatched to the address of the Applicants as registered with the depositories / as filled in the application form on or before 8th May, 2018. Further, the instructions to Self Certified Syndicate Banks being processed on or prior to 8th May, 2018. In case the same is not received within 10 days, investors may contact at the address given below The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is taking steps to get the Equity Shares admitted for trading on the SME Platform of BSE Limited within six working days from the date of the closure of the Issue The trading is proposed to be commenced on or before 9th May, 2018 subject to receipt of listing and trading approvals from BSE Limited. INVESTORS PLEASE NOTE The details of the allotment made would also be hosted on the website of the Registrar to the Issue. Cameo Corporate Services Limited at All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quotng full name of the first/ Sole applicants, serial number of the Application Form, number of shares applied for and ASBA Bank details at the address of the Registrar given below: CAMEO CORPORATE SERVICES LTD.
|
The Dr Lalchandani Labs IPO basis of allotment (published above) tells you how shares are allocated to you in Dr Lalchandani Labs IPO and category wise demand of IPO share.
Visit the Dr Lalchandani Labs IPO allotment status page to check the number of shares allocated to your application.
Useful Articles
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
